Thursday, January 24, 2013

Immunogenicity Session Spotlight: Using the Aushon BioSystems Technology to Develop a Sensitive, Drug Tolerant Screening Assay

With so many different varieties of assays available, it is important for bioanalytical professionals to weigh considerations such as sensitivity, precision, drug tolerance, and cost. In today's featured Immunogenicity for Biotherapeutics session spotlight, we explore all of the important criteria as part of a case study of a new favored assay method in the session Using the Aushon BioSystems Technology to Develop a Sensitive, Drug Tolerant Screening Assay.

Immunogenicity for Biotherapeutics will take place March 18-20, 2013 in Baltimore, Maryland.  For more information on this session and the entire event, download the agenda.  If you'd like to join us in Baltimore register today and mention code XP1838BLOG to save 15% off the standard rate!

Featured Session: Case Study - Using the Aushon BioSystems Technology to Develop a Sensitive, Drug Tolerant Screening Assay

Featured Speaker: Jo Goodman, Senior R&D Manager, Bioanalytical Sciences, MEDIMMUNE

About the session: In order to detect an immunogenic response, there is a regulatory requirement to develop appropriate assays using a multi-tiered approach. These assays should be sensitive, with a low and defined false positive rate, and detect all isotype responses. Many different assay platforms are available, each with their own advantages and disadvantages. Factors such as sensitivity, precision, drug tolerance and even cost are important considerations.
  • • Current assay platforms employed to develop screening and confirmatory assays
  • • Understand the Aushon BioSystems Technology and how it can be employed for the development of immunogenicity assays
  • • Case Study data


Share this article with your social network, just click below to share now!


No comments :

Post a Comment